Up to today, acetylcholinesterase (AChE) is an attractive target for the treatment of Alzheimer’s disease, and acetylcholinesterase inhibitors represent the major approved drugs to treat this neurodegenerative disease (37). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.